344 related articles for article (PubMed ID: 28710924)
1. Identification of new BACE1 inhibitors using Pharmacophore and Molecular dynamics simulations approach.
Dhanabalan AK; Kesherwani M; Velmurugan D; Gunasekaran K
J Mol Graph Model; 2017 Sep; 76():56-69. PubMed ID: 28710924
[TBL] [Abstract][Full Text] [Related]
2. Molecular docking based virtual screening of natural compounds as potential BACE1 inhibitors: 3D QSAR pharmacophore mapping and molecular dynamics analysis.
Kumar A; Roy S; Tripathi S; Sharma A
J Biomol Struct Dyn; 2016; 34(2):239-49. PubMed ID: 25707809
[TBL] [Abstract][Full Text] [Related]
3. Molecular insights into the inhibitory mechanism of bi-functional bis-tryptoline triazole against β-secretase (BACE1) enzyme.
Narang SS; Goyal D; Goyal B
Amino Acids; 2019 Nov; 51(10-12):1593-1607. PubMed ID: 31654211
[TBL] [Abstract][Full Text] [Related]
4. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
Iqbal S; Anantha Krishnan D; Gunasekaran K
J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
[TBL] [Abstract][Full Text] [Related]
5. Computational modelling of potent β-secretase (BACE1) inhibitors towards Alzheimer's disease treatment.
Ugbaja SC; Sanusi ZK; Appiah-Kubi P; Lawal MM; Kumalo HM
Biophys Chem; 2021 Mar; 270():106536. PubMed ID: 33387910
[TBL] [Abstract][Full Text] [Related]
6. Modeling the protonation states of β-secretase binding pocket by molecular dynamics simulations and docking studies.
Sabbah DA; Zhong HA
J Mol Graph Model; 2016 Jul; 68():206-215. PubMed ID: 27474865
[TBL] [Abstract][Full Text] [Related]
7. Asp32 and Asp228 determine the selective inhibition of BACE1 as shown by docking and molecular dynamics simulations.
Hernández-Rodríguez M; Correa-Basurto J; Gutiérrez A; Vitorica J; Rosales-Hernández MC
Eur J Med Chem; 2016 Nov; 124():1142-1154. PubMed ID: 27639619
[TBL] [Abstract][Full Text] [Related]
8. Dynamic Simulation, Docking and DFT Studies Applied to a Set of Anti-Acetylcholinesterase Inhibitors in the enzyme β-Secretase (BACE-1): An Important Therapeutic Target in Alzheimer`s disease.
Silva-Junior EF; Barcellos Franca PH; Quintans-Junior LJ; Mendonca-Junior FJB; Scotti L; Scotti MT; de Aquino TM; de Araujo-Junior JX
Curr Comput Aided Drug Des; 2017 Nov; 13(4):266-274. PubMed ID: 28382866
[TBL] [Abstract][Full Text] [Related]
9. Identification of Novel BACE1 Inhibitors by Combination of Pharmacophore Modeling, Structure-Based Design and In Vitro Assay.
Ju Y; Li Z; Deng Y; Tong A; Zhou L; Luo Y
Curr Comput Aided Drug Des; 2016; 12(1):73-82. PubMed ID: 26899408
[TBL] [Abstract][Full Text] [Related]
10. β-secretase inhibitors for Alzheimer's disease: identification using pharmacoinformatics.
Islam MA; Pillay TS
J Biomol Struct Dyn; 2019 Feb; 37(2):503-522. PubMed ID: 29388503
[TBL] [Abstract][Full Text] [Related]
11. BACE1 Inhibition by Genistein: Biological Evaluation, Kinetic Analysis, and Molecular Docking Simulation.
Youn K; Park JH; Lee S; Lee S; Lee J; Yun EY; Jeong WS; Jun M
J Med Food; 2018 Apr; 21(4):416-420. PubMed ID: 29444415
[TBL] [Abstract][Full Text] [Related]
12. Conformational dynamics of cathepsin D and binding to a small-molecule BACE1 inhibitor.
Ellis CR; Tsai CC; Lin FY; Shen J
J Comput Chem; 2017 Jun; 38(15):1260-1269. PubMed ID: 28370344
[TBL] [Abstract][Full Text] [Related]
13. In silico screening of potential β-secretase (BACE1) inhibitors from VIETHERB database.
Nhung NT; Duong N; Phung HTT; Vo QV; Tam NM
J Mol Model; 2022 Feb; 28(3):60. PubMed ID: 35156141
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore based 3D-QSAR modeling, virtual screening and docking for identification of potential inhibitors of β-secretase.
Palakurti R; Vadrevu R
Comput Biol Chem; 2017 Jun; 68():107-117. PubMed ID: 28288354
[TBL] [Abstract][Full Text] [Related]
15. Hybrid structure-based virtual screening protocol for the identification of novel BACE1 inhibitors.
Vijayan RS; Prabu M; Mascarenhas NM; Ghoshal N
J Chem Inf Model; 2009 Mar; 49(3):647-57. PubMed ID: 19434899
[TBL] [Abstract][Full Text] [Related]
16. Determination of the protonation state for the catalytic dyad in β-secretase when bound to hydroxyethylamine transition state analogue inhibitors: A molecular dynamics simulation study.
Gueto-Tettay C; Pestana-Nobles R; Drosos-Ramirez JC
J Mol Graph Model; 2016 May; 66():155-67. PubMed ID: 27111489
[TBL] [Abstract][Full Text] [Related]
17. Identification of new BACE1 inhibitors for treating Alzheimer's disease.
Kushwaha P; Singh V; Somvanshi P; Bhardwaj T; Barreto GE; Ashraf GM; Mishra BN; Chundawat RS; Haque S
J Mol Model; 2021 Jan; 27(2):58. PubMed ID: 33517514
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of quinazolinone-based hydrazones with potential use in Alzheimer's disease.
Haghighijoo Z; Firuzi O; Hemmateenejad B; Emami S; Edraki N; Miri R
Bioorg Chem; 2017 Oct; 74():126-133. PubMed ID: 28780149
[TBL] [Abstract][Full Text] [Related]
19. Flexibility of the flap in the active site of BACE1 as revealed by crystal structures and molecular dynamics simulations.
Xu Y; Li MJ; Greenblatt H; Chen W; Paz A; Dym O; Peleg Y; Chen T; Shen X; He J; Jiang H; Silman I; Sussman JL
Acta Crystallogr D Biol Crystallogr; 2012 Jan; 68(Pt 1):13-25. PubMed ID: 22194329
[TBL] [Abstract][Full Text] [Related]
20. Alzheimer's Disease and β-secretase Inhibition: An Update with a Focus on Computer-aided Inhibitor Design.
Ugbaja SC; Lawal IA; Kumalo HM; Lawal MM
Curr Drug Targets; 2022; 23(3):266-285. PubMed ID: 34370634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
